---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-003765"
form_type: "8-K"
ticker: "NXL"
cik: "0001527352"
company_name: "Nexalin Technology, Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:53:26.033635+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nexalin advances pivotal HALO Clarity insomnia trial toward Q2 2026 enrollment with 160-patient study

## Summary
- Entered contract with Lindus Health for pivotal study; direct fees ~$944,820 plus pass-through expenses.
- 160-patient, triple-blinded, sham-controlled trial targeting moderate-to-severe insomnia.
- Enrollment expected to begin Q2 2026; study supports planned De Novo FDA submission.
- Published peer-reviewed data showed statistically significant improvements vs sham treatment.
- Global sleep tech market estimated at $29.3B in 2025, projected to reach $153.7B by 2035.

## SEC filing metadata
- accession: 0001829126-26-003765
- form_type: 8-K
- ticker: NXL
- cik: 0001527352
- company_name: Nexalin Technology, Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527352/000182912626003765/0001829126-26-003765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527352/000182912626003765/nexalintec_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-003765
- JSON: https://secwatch.observer/filing/0001829126-26-003765.json
- Plain text: https://secwatch.observer/filing/0001829126-26-003765.txt

## Source-grounded claims
- claim_id: 106abf9a9e4abb8b3b4712112de00d127e7226a2
  claim: Nexalin Technology, Inc. entered into Scope of Work with Lindus Health Limited valued at approximately $944,820 (effective 2026-04-17).
  evidence_excerpt: On April 17, 2026, Nexalin Technology, Inc. (the “Company”) entered into a Scope of Work (the “SOW”) with Lindus Health Limited (“Lindus Health”), a clinical research organization based in the United Kingdom.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527352/000182912626003765/0001829126-26-003765-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.